Feasibility and safety of extended‐release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial
| Autor: | Keith Ahamad, Philip T. Korthuis, Doan Ha, Paula J. Lum, Lynn E. Kunkel, Evan Wood, Neal Oden, Robert Lindblad, Pamela Vergara-Rodriguez, James L. Sorensen, Virgilio Arenas, Dennis McCarty, Raul N. Mandler |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Male
0301 basic medicine medicine.medical_specialty Randomization Narcotic Antagonists Medicine (miscellaneous) HIV Infections Pilot Projects Alcohol use disorder Article Naltrexone law.invention 03 medical and health sciences 0302 clinical medicine Pharmacotherapy Randomized controlled trial law Internal medicine Injection site reaction medicine Humans CTN-0055 CHOICES Investigators 030212 general & internal medicine Psychiatry Chicago British Columbia business.industry Opioid use disorder Middle Aged Opioid-Related Disorders medicine.disease 030112 virology Alcoholism Psychiatry and Mental health Treatment Outcome Opioid Delayed-Action Preparations Feasibility Studies Female business human activities medicine.drug |
| Zdroj: | Korthuis, PT; Lum, PJ; Vergara-Rodriguez, P; Ahamad, K; Wood, E; Kunkel, LE; et al.(2017). Feasibility and safety of extended-release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial. Addiction, 112(6), 1036-1044. doi: 10.1111/add.13753. UCSF: Retrieved from: http://www.escholarship.org/uc/item/7wx9p0hz |
| ISSN: | 1360-0443 0965-2140 |
| Popis: | © 2017 Society for the Study of Addiction Background and aims: HIV-infected people with substance use disorders are least likely to benefit from advances in HIV treatment. Integration of extended-release naltrexone (XR-NTX) into HIV clinics may increase engagement in the HIV care continuum by decreasing substance use. We aimed to compare (1) XR-NTX treatment initiation, (2) retention and (3) safety of XR-NTX versus treatment as usual (TAU) for treating opioid use disorder (OUD) and/or alcohol use disorder (AUD) in HIV clinics. Design: Non-blinded randomized trial of XR-NTX versus pharmacotherapy TAU. Setting: HIV primary care clinics in Vancouver, BC, Canada and Chicago, IL, USA. Participants: Fifty-one HIV-infected patients seeking treatment for OUD (n = 16), AUD (n = 27) or both OUD and AUD (n = 8). Measurements: Primary outcomes were XR-NTX initiation (receipt of first injection within 4 weeks of randomization) and retention at 16 weeks. Secondary outcomes generated point estimates for change in substance use, HIV viral suppression [HIV RNA polymerase chain reaction (pcr) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|